Big Pharma CCHT’s Domination Unlikely to Fade Soon Despite Official Bulk Buying
The producer of long-acting growth hormone acupunctures, vaccines and other drugs, looks set to offset the effects of so-called “centralized procurement” on its product prices with more aggressive expansion into private hospitals. So far, its monopoly appears unshakable, but with more competitors upping the stakes, how long will it last?
Feb 21, 2022 02:30 PM
China’s Food and Beverage Industry in Search of Methods to Shrink its Carbon Footprints
EqualOcean | Southern Weekly 2022 'China Greenwashing List'
Oct 03, 2023 12:37 PM
2022 ESG Report Analysis | Yili: The Practical Path of ESG
Sep 28, 2023 09:01 PM
An Analysis of Domestic ESG Rating Agencies in China
Sep 28, 2023 12:46 PM